MedTech News
.................... by Andrew Celentano
For the tiniest patients, new tech brings clearer MRI images
Some of medicine’s smallest patients can present its biggest imaging challenges. An infant’s heart can be as small as a walnut, beating rapidly inside a body that will change dramatically as the child grows. Yet much of the equipment used in MRI comes in standard sizes better suited to adult bodies, and customized versions can cost thousands of dollars and take months or even years to manufacture.
Sweat sensor enables continuous noninvasive measurement of cholesterol
Now, a team led by Wei Gao, a professor in Caltech’s Cherng Department of Medical Engineering, has developed a stick-on patch capable of gathering lipid measurements by analyzing sweat. And it can do so not just once but continuously.
Bracco’s VueJect contrast system secures FDA and Health Canada approvals
The device will be sold initially in the US and Canada, with further submissions planned in additional markets.
Wandercraft wins FDA clearance for self-balancing exoskeleton
Wandercraft, a Paris-based robotics company, announced that the FDA has granted clearance for Eve, its personal self-balancing exoskeleton designed to support upright mobility.
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.
Bracco Marks Major Global Milestone with U.S. FDA 510(k) Clearance and Health Canada Authorization for VueJect®, the First Dedicated Ultrasound Contrast Delivery System to Support Cardiology Imaging
MILAN, Aug. 11, 2026 /PRNewswire/ — Bracco Imaging today announced that VueJect®, its first dedicated ultrasound contrast delivery system engineered to support cardiology imaging specifically, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and authorization from Health Canada.
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
HOUSTON, Aug. 11, 2026 /PRNewswire/ — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,691,147, entitled “Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment.” The patent describes methods utilizing fibroblasts to improve the engraftment and long-term function of transplanted pancreatic islets, addressing one of the major challenges in islet transplantation.
Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device
BEIJING, Aug. 11, 2026 /PRNewswire/ — Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) (“Datasea” or the “Company”), a technology company focused on acoustic high-tech and AI multimodal digital solutions, today announced that Shuhai Jingwei (Shenzhen) Information Technology Co., Ltd. (“Shuhai Jingwei”), the Company’s variable interest entity in China, has completed establishment registration and device listing with the U.S. Food and Drug Administration (“FDA”) for its NeuroVibe Biofeedback System, including products NV-02 and NV-03.